MedTrace Logo

Effects of 5HTP and LDOPA on CNS Excitability After SCI

NCT04000919 · Status: SUSPENDED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-17

No results posted yet for this study

Summary

This study will examine whether supplementation with the serotonin and dopamine precursors, 5HTP and L-DOPA can alter central nervous system excitability and improve motor function after incomplete and complete spinal cord injuries.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

5HTP

5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)

DRUG

L-DOPA

L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)

DRUG

Placebo oral tablet

Placebo

DRUG

Carbidopa

Carbidopa (50mg)

Sponsors & Collaborators

  • Jessica M D'Amico

    lead OTHER

Principal Investigators

  • Jessica D'Amico, PhD · University of Louisville

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2023-06-30
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04000919 on ClinicalTrials.gov